Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration Trials
April 20 2023 - 5:00PM
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a
clinical-stage pharmaceutical company focused on developing next
generation oral and IV antibiotics to treat infections caused by
multi-drug resistant pathogens in both community and hospital
settings, today announced that two posters were presented at the
33rd Annual European Congress of Clinical Microbiology and
Infectious Disease (ECCMID) held in Copenhagen.
The posters presented at ECCMID were:
- Title: Desirability of outcome ranking (DOOR):
application to a phase 3 registrational trial evaluating sulopenem
for patients with uncomplicated urinary tract infection
(uUTI)Presenting Author: Sailaja Puttagunta, MD
Date: April 17, 2023
- Title: Desirability of outcome ranking (DOOR):
application to a phase 3 registrational trial evaluating sulopenem
for patients with complicated urinary tract infection
(cUTI)Presenting Author: Sailaja Puttagunta, MD
Date: April 17, 2023
The desirability of outcome ranking (DOOR), not
yet accepted by regulatory authorities as a primary endpoint for
urinary tract infection studies, is a novel method of analyzing
data from clinical trials taking into account both benefits and
harms of drugs being evaluated and providing an assessment of the
patient experience. It was utilized recently by the Antibacterial
Resistance Leadership Group (ARLG) to develop a method to evaluate
data from completed pivotal cUTI trials. “Applying the ARLGs
approach retrospectively to our two Phase 3 studies of sulopenem,
one each in cUTI and uUTI, respectively, demonstrated that oral
sulopenem was comparably more effective than ciprofloxacin in
patients with uUTI and provided comparable efficacy to ertapenem in
patients with cUTI,” said Dr. Sailaja Puttagunta, Chief Medical
Officer of Iterum Therapeutics.
These Posters are available on the Company’s
website on the “Publications: Posters & Presentations” page
under the “Our Science” tab.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage
pharmaceutical company dedicated to developing differentiated
anti-infectives aimed at combatting the global crisis of multi-drug
resistant pathogens to significantly improve the lives of people
affected by serious and life-threatening diseases around the world.
Iterum is currently advancing its first compound, sulopenem, a
novel penem anti-infective compound, in Phase 3 clinical
development with an oral formulation. Sulopenem also has an IV
formulation. Sulopenem has demonstrated potent in vitro activity
against a wide variety of gram-negative, gram-positive and
anaerobic bacteria resistant to other antibiotics. Iterum has
received Qualified Infectious Disease Product (QIDP) and Fast Track
designations for its oral and IV formulations of sulopenem in seven
indications. For more information, please visit
http://www.iterumtx.com.
Investor Contact:Judy
MatthewsChief Financial Officer 312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Jul 2023 to Jul 2024